Abstract
Purulent pericarditis is rarely seen in this post-antibiotic era. We report a case of spontaneous purulent pericarditis in a patient with rheumatoid arthritis being treated with etanercept, a tumour necrosis factor-alpha (TNF-alpha) antagonist, and methotrexate, an immunosuppressant. Both are disease-modifying anti-rheumatic drugs. We discuss the pathophysiology of purulent pericarditis and the recent literature on the infectious complications of TNF-alpha antagonists.
MeSH terms
-
Aged
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / drug therapy
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects*
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects*
-
Pericarditis / microbiology*
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Staphylococcal Infections / diagnosis
-
Staphylococcus aureus / isolation & purification
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept
-
Methotrexate